MXPA03005941A - Analogos tacrolimus neurotroficos. - Google Patents

Analogos tacrolimus neurotroficos.

Info

Publication number
MXPA03005941A
MXPA03005941A MXPA03005941A MXPA03005941A MXPA03005941A MX PA03005941 A MXPA03005941 A MX PA03005941A MX PA03005941 A MXPA03005941 A MX PA03005941A MX PA03005941 A MXPA03005941 A MX PA03005941A MX PA03005941 A MXPA03005941 A MX PA03005941A
Authority
MX
Mexico
Prior art keywords
compound
nerve
spinal cord
growth
cell
Prior art date
Application number
MXPA03005941A
Other languages
English (en)
Spanish (es)
Inventor
Goldberg Bruce
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of MXPA03005941A publication Critical patent/MXPA03005941A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Packages (AREA)
  • Saccharide Compounds (AREA)
MXPA03005941A 2000-12-29 2001-12-31 Analogos tacrolimus neurotroficos. MXPA03005941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29
PCT/US2001/050419 WO2002053159A1 (fr) 2000-12-29 2001-12-31 Analogues de tacrolimus neurotrophiques

Publications (1)

Publication Number Publication Date
MXPA03005941A true MXPA03005941A (es) 2005-02-14

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005941A MXPA03005941A (es) 2000-12-29 2001-12-31 Analogos tacrolimus neurotroficos.

Country Status (18)

Country Link
EP (1) EP1353671A4 (fr)
JP (1) JP2004527472A (fr)
KR (2) KR100794204B1 (fr)
CN (1) CN1293877C (fr)
AR (1) AR035411A1 (fr)
AU (1) AU2002231277B2 (fr)
BR (1) BR0116762A (fr)
CA (1) CA2433384A1 (fr)
CZ (1) CZ20032060A3 (fr)
HU (1) HUP0302521A3 (fr)
IL (1) IL156664A0 (fr)
MX (1) MXPA03005941A (fr)
NO (1) NO20032913D0 (fr)
NZ (1) NZ527209A (fr)
PL (1) PL366301A1 (fr)
RU (1) RU2288716C2 (fr)
WO (1) WO2002053159A1 (fr)
ZA (1) ZA200305806B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
JP2007518692A (ja) * 2004-01-20 2007-07-12 アステラス製薬株式会社 勃起不全治療方法
EP1810675A1 (fr) * 2006-01-18 2007-07-25 Institut Curie Methode de traitement de la maladie de Huntington par l'inhibition de la dephosphorylation de la S421
JP2009102226A (ja) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd 脊髄損傷治療剤
CA2730751A1 (fr) * 2008-07-23 2010-01-28 Novartis Ag Modulateurs du recepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire
EP2817009A1 (fr) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Inhibiteurs de la calcineurine destinés à être utilisés dans le traitement des troubles vestibulaires entraînant des lésions
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2799208B2 (ja) * 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use

Also Published As

Publication number Publication date
EP1353671A1 (fr) 2003-10-22
KR100794204B1 (ko) 2008-01-14
CA2433384A1 (fr) 2002-07-11
NO20032913D0 (no) 2003-06-24
AR035411A1 (es) 2004-05-26
HUP0302521A3 (en) 2007-03-28
AU2002231277B2 (en) 2006-11-30
KR20070030331A (ko) 2007-03-15
CN1538843A (zh) 2004-10-20
JP2004527472A (ja) 2004-09-09
ZA200305806B (en) 2005-01-26
EP1353671A4 (fr) 2004-07-14
NZ527209A (en) 2005-09-30
CN1293877C (zh) 2007-01-10
RU2288716C2 (ru) 2006-12-10
HUP0302521A2 (hu) 2003-11-28
RU2003123493A (ru) 2005-01-20
CZ20032060A3 (cs) 2004-01-14
KR20040007431A (ko) 2004-01-24
IL156664A0 (en) 2004-01-04
PL366301A1 (en) 2005-01-24
WO2002053159A1 (fr) 2002-07-11
BR0116762A (pt) 2004-08-10

Similar Documents

Publication Publication Date Title
Cui et al. CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters.
Gaviria et al. Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats
Yin et al. Taxol-modified collagen scaffold implantation promotes functional recovery after long-distance spinal cord complete transection in canines
MX2009002063A (es) Tratamiento de desordenes en cartilagos con factor de crecimiento de fibroblastos-18.
CH689541A5 (de) Inhibitoren der Enzymaktivität von Rotamase.
AU1668599A (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
DE69635754T2 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
AU2002231277B2 (en) Neurotrophic tacrolimus analogs
AU2002231277A1 (en) Neurotrophic tacrolimus analogs
US20040077676A1 (en) Neurotrophic tacrolimus analogs
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物
US11969522B2 (en) Use of immune modulators to improve nerve regeneration
Itoh et al. The effect of neurotrophic pyrimidine heterocyclic compounds, MS-818 and MS-430, on the regeneration of injured peripheral nerves
CA2455896A1 (fr) Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil
US6476001B1 (en) Facilitation of repair of neural injury with CM101/GBS toxin
US6852496B1 (en) Methods of screening for agents that promote nerve cell growth
US20040162315A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
CN101690728B (zh) 一种治疗骨性关节炎的组合物
EP2724723A1 (fr) Tégasérod pour un usage dans le traitement de lésions nerveuses
EP3362059B1 (fr) Nouvelles thérapies combinées pour le traitement de lésions neurologiques
CN1270727C (zh) 一种治疗脊髓损伤的治疗剂
AU2002322700A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration